Updated:
Daylight Partners
Daylight Capital is a boutique Biotech Investment Fund specializing in emerging technologies. It utilizes the principles of value investing to mitigate risk...
Daylight Partners
Daylight Capital is a boutique Biotech Investment Fund specializing in emerging technologies. It utilizes the principles of value investing to mitigate risk and maximize returns within the biotechnology sector. Its unique expertise resides in opportunity identification and data interpretation to predict regulatory outcomes and monetize catalytic events.
General information
Firm type
Private Equity
Year founded
2008
Location
Region
North America
Country
United States
City
Austin
Corporate office
Austin, TX, United States
Sector focus
Frequently asked questions
What specific biotech subsectors does Daylight Capital target?
Daylight Capital's public materials reference a focus on emerging technologies within the biotechnology sector broadly. It does not break down specific therapeutic areas or modalities, such as gene editing or oncology, on its website. The firm's investment thesis centers on data interpretation to predict regulatory outcomes rather than on any single scientific niche.
How does Daylight Capital apply value investing to biotechnology?
The firm describes its approach as using value investing principles to mitigate the inherent binary risk in biotech. It aims to identify opportunities where the market has mispriced the likelihood of regulatory approval or a positive catalytic event. This event-driven strategy attempts to capture returns from discrete milestones rather than long-term drug development.
Who manages the investment decisions at Daylight Capital?
Daylight Capital discloses no named principals, portfolio managers, or analysts on its website. No LinkedIn page was captured in Altss research, and no regulatory filings or press releases naming its founders or investment committee members were located. The firm's leadership structure remains entirely opaque.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: